Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-PD-1 antibody decreases tumour-infiltrating regulatory T cells
Authors
Keywords
-
Journal
BMC CANCER
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-01-08
DOI
10.1186/s12885-019-6499-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
- (2019) Miren Zuazo et al. EMBO Molecular Medicine
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse
- (2018) Bingxin Zheng et al. Journal of Hematology & Oncology
- DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation
- (2018) Qian Xiao et al. NATURE MEDICINE
- Immunotherapy for osteosarcoma: Where do we go from here?
- (2018) Mary F. Wedekind et al. PEDIATRIC BLOOD & CANCER
- A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer
- (2018) Wei You et al. Journal of Cancer
- Inhibitory Receptors and Pathways of Lymphocytes: The Role of PD-1 in Treg Development and Their Involvement in Autoimmunity Onset and Cancer Progression
- (2018) Elena Gianchecchi et al. Frontiers in Immunology
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
- (2017) Hussein A Tawbi et al. LANCET ONCOLOGY
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial
- (2017) Anne Gomez-Brouchet et al. OncoImmunology
- Dual Faces of IFN in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity
- (2016) M. Mandai et al. CLINICAL CANCER RESEARCH
- Roles of regulatory T cells in cancer immunity
- (2016) Yoshiko Takeuchi et al. INTERNATIONAL IMMUNOLOGY
- Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model
- (2016) Baihao Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma
- (2016) Yuki Honda et al. OncoImmunology
- PD-1 Upregulated on Regulatory T Cells during Chronic Virus Infection Enhances the Suppression of CD8+T Cell Immune Response via the Interaction with PD-L1 Expressed on CD8+T Cells
- (2015) Hyo Jin Park et al. JOURNAL OF IMMUNOLOGY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review)
- (2014) SADEK MALAS et al. ONCOLOGY REPORTS
- Programmed Cell Death Ligand 1 Expression in Osteosarcoma
- (2014) J. K. Shen et al. Cancer Immunology Research
- PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction
- (2013) K. Abiko et al. CLINICAL CANCER RESEARCH
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Immunology beats cancer: a blueprint for successful translation
- (2012) Drew M Pardoll NATURE IMMUNOLOGY
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- Tumor-reactive CD4+T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
- (2010) Sergio A. Quezada et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
- (2010) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Regulatory T Cells: Mechanisms of Differentiation and Function
- (2007) Steven Z. Josefowicz et al. Annual Review of Immunology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started